# EDGAR Filing Document

**Accession Number:** 0000078003
**File Stem:** 0000078003-26-000022
**Filing Date:** 2026-2
**Character Count:** 12168
**Document Hash:** a4f8d0dabb10da02074e87689a1c209a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000078003-26-000022.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0000078003-26-000022

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Allogene Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001737287
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823562771
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90685
- **FILM NUMBER:** 26634464

**BUSINESS ADDRESS:**
- **STREET 1:** 210 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 457-2700

**MAIL ADDRESS:**
- **STREET 1:** 210 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PFIZER INC
- **CENTRAL INDEX KEY:** 0000078003
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 135315170
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 66 HUDSON BOULEVARD EAST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001-2192
- **BUSINESS PHONE:** 2127332323

**MAIL ADDRESS:**
- **STREET 1:** 66 HUDSON BOULEVARD EAST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001-2192

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PFIZER CHARLES & CO INC
- **DATE OF NAME CHANGE:** 19710908

## Exhibit 99.1

**Schedule I**

**Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of Pfizer**

The business address of each director and executive officer is c/o Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001. Unless otherwise indicated, each director and executive officer is a citizen of the United States.

---

| | |
|:---|:---|
| **NAME AND POSITION** | **PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT** |
| **Albert Bourla, DVM, Ph.D.**<br>Chairman and Chief Executive Officer | Chairman and Chief Executive Officer, Pfizer. |
| **Ronald E. Blaylock**<br>Independent Director | Founder, Managing Partner of GenNx360 Capital Partners. |
| **Mortimer J. Buckley**<br>Independent Director | Former Chairman and Chief Executive Officer of Vanguard Group Inc. |
| **Susan Desmond-Hellmann, M.D., M.P.H.** <br>Independent Director | Former Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute. |
| **Joseph J. Echevarria** <br>Independent Director | Retired Chief Executive Officer of Deloitte LLP. |
| **Scott Gottlieb, M.D.**<br>Independent Director | Partner, New Enterprise Associates, Inc.'s Healthcare Investment Team and Senior Fellow of the American Enterprise Institute. |
| **Susan Hockfield, Ph.D.**<br>Independent Director | Professor of Neuroscience and President Emerita, Massachusetts Institute of Technology. |
| **Dan R. Littman, M.D., Ph.D.**<br>Independent Director | Helen L. and Martin S. Kimmel Professor of Molecular Immunology, Department of Pathology at NYU Grossman School of Medicine. Investigator of the Howard Hughes Medical Institute. |
| **Shantanu Narayen**<br>Lead Independent Director | Chairman and Chief Executive Officer of Adobe Inc. |
| **Suzanne Nora Johnson** <br>Independent Director | Retired Vice Chairman, Goldman Sachs Group, Inc. |
| **James Quincey**<br>Independent Director | Chairman and Chief Executive Officer, The Coca-Cola Company. Country of citizenship United Kingdom. |
| **James C. Smith**<br>Independent Director | Chairman of the Thomson Reuters Foundation. Retired President and Chief Executive Officer of Thomson Reuters Corporation. |
| **Cyrus Taraporevala**<br>Independent Director | Former President and Chief Executive Officer of State Street Global Advisors. |
| **Andrew Baum**<br>Chief Strategy and Innovation Officer, Executive Vice President | Chief Strategy and Innovation Officer, Executive Vice President, Pfizer. <br>Country of citizenship United Kingdom |
| **Chris Boshoff, FRCP, FMedSci, Ph.D.**<br>Chief Scientific Officer and President, Research & Development | Chief Scientific Officer and President, Research & Development, Pfizer. |

---

------

---

| | |
|:---|:---|
| **Alexandre de Germay**<br>Chief International Commercial Officer, Executive Vice President | Chief International Commercial Officer, Executive Vice President., Pfizer. <br>Country of citizenship France. |
| **David M. Denton**<br>Chief Financial Officer, Executive Vice President | Chief Financial Officer, Executive Vice President, Pfizer. |
| **Lidia Fonseca**<br>Chief Digital and Technology Officer, Executive Vice President | Chief Digital and Technology Officer, Executive Vice President, Pfizer. |
| **Douglas M. Lankler**<br>Chief Legal Officer, Executive Vice President | Chief Legal Officer, Executive Vice President, Pfizer. |
| **Aamir Malik**<br>Chief U.S. Commercial Officer, Executive Vice President | Chief U.S. Commercial Officer, Executive Vice President, Pfizer. |
| **Michael McDermott**<br>Chief Global Supply Officer, Executive Vice President | Chief Global Supply Officer, Executive Vice President, Pfizer. |
| **Payal Sahni Becher**<br>Chief People Experience Officer, Executive Vice President | Chief People Experience Officer, Executive Vice President, Pfizer. |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**Allogene Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share (the "Common Stock")**

*(Title of Class of Securities)*

**019770106**

*(CUSIP Number)*

**Margaret M. Madden, Esq**<br>66 Hudson Boulevard East<br>New York NY 10001<br>212-733-2323

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/06/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **019770106** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pfizer Inc.** | Name of reporting person<br>**Pfizer Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**22032040.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**22032040.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**22032040.00** | Aggregate amount beneficially owned by each reporting person<br>**22032040.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.0%** | Percent of class represented by amount in Row (11)<br>**9.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Percent of class represented by amount in row (11) is calculated based upon 224,730,144 shares of common stock, $0.001 par value per share, outstanding as of November 4, 2025, as reported by the Issuer on the cover of its Form 10-Q for the quarterly period ended September 30, 2025 and filed with the U.S. Securities and Exchange Commission on November 6, 2025 (the "Form 10-Q").  The decrease in the percentage of shares of Common Stock held by the Reporting Person reported on this Amendment No. 4 resulted solely from the increase in the number of shares of Common Stock reported as outstanding by the Issuer in the Form 10-Q.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share (the "Common Stock")

**(b) Name of Issuer:**
Allogene Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
210 East Grand Avenue, South San Francisco, CA, 94080

Explanatory Note

This Amendment No. 4 (this "Amendment No. 4") to the statement on Schedule 13D originally filed with the U.S. Securities and Exchange Commission (the "Commission") on October 22, 2018, as amended by Amendment No. 1 filed on September 17, 2021, Amendment No. 2 filed on April 7, 2022 and Amendment No. 3 filed on October 25, 2023 (the "Schedule 13D"), relates to the common stock, par value $0.001 per share (the "Common Stock"), of Allogene Therapeutics, Inc., a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 210 East Grand Avenue, South San Francisco, California 94080. The Issuer's shares of Common Stock are listed on The Nasdaq Stock Market LLC under the ticker symbol "ALLO".
Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not otherwise defined in this Amendment No. 4 shall have the meanings ascribed to them in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**Item 4. Purpose of Transaction**

No amendment to this Item is being made.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The paragraphs captioned (a) - (b) of Item 5 of the Schedule 13D are hereby superseded by the following paragraphs:

(a)--(b) The information related to the beneficial ownership of Common Stock by the Reporting Person set forth in Rows 7 through 13 of the cover page hereto is incorporated by reference.  The decrease in the percentage of shares of Common Stock held by the Reporting Person reported on this Amendment No. 4 resulted solely from the increase in the number of shares of Common Stock reported as outstanding by the Issuer in the Form 10-Q for the quarterly period ended September 30, 2025 as filed with the U.S. Securities and Exchange Commission on November 6, 2025.

**(b)**
See (a).

**(c)**
The paragraph captioned (c) in the Schedule 13D is hereby supersed by the following paragraph:                                                                                                                                                                                                                                   (c) Except as reported in the Schedule 13D, neither the Reporting Person nor any of the Individuals listed on Schedule I has effected any transactions in the Common Stock during the past sixty (60) days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

No amendment to this Item is being made.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pfizer Inc.

**Signature:** /s/ Madelyn D. Purcell

**Name/Title:** Madelyn D. Purcell/Assistant Secretary

**Date:** 02/13/2026